Telo Genomics Corp.
TDSGF
Rank in Stocks
#31328
Telo Genomics Corp. (TELO.V) operates as a biotechnology firm focused on... Telo Genomics Corp. (TELO.V) operates as a biotechnology firm focused on creating and bringing to market advanced predictive solutions. Its core mission is to enable personalized treatment approaches for individuals suffering from specific health conditions. The company's primary innovation is a sophisticated telomere analysis platform, which serves both to diagnose diseases and to forecast patient outcomes. This technology, often integrated with liquid biopsies, provides crucial insights for applications in both cancer and neurological illnesses. Their leading product, Telo-MM, is specifically designed to arm medical professionals with vital, actionable information for effectively managing Multiple Myeloma, a serious blood cancer. Additionally, Telo Genomics offers TeloView, a proprietary software system capable of precisely measuring individual patient telomere characteristics. Telo Genomics caters to a broad spectrum of clients, including diagnostic pathologists, clinical doctors, academic researchers, and pharmaceutical developers. A notable endorsement of its technology is a collaborative agreement with the renowned Mayo Clinic, aimed at validating the Telo-MM diagnostic tests for multiple myeloma. Founded in 2014 and based in Toronto, Canada, the company adopted its current name, Telo Genomics Corp., in April 2019, having previously operated as 3D Signatures Inc.
Share Price
$0.03
Last synced: 2026-11-13
Market Cap
$3.17M
Change (1 day)
0.00%
Change (1 year)
-24.62%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Telo Genomics Corp. (TDSGF)
Category
Healthcare
EPS for Telo Genomics Corp. (TDSGF)
EPS as of June 2026 TTM: $-0.02
According to Telo Genomics Corp.'s latest financial reports, its current EPS (TTM) is $-0.02. At the end of 2025 the company had an EPS of $-0.02, an increase over its 2024 EPS of $-0.03.
EPS history for Telo Genomics Corp. from 2012 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.02 | -20.00% |
| 2025 | $-0.02 | -39.57% |
| 2024 | $-0.03 | -21.47% |
| 2023 | $-0.04 | 92.39% |
| 2021 | $-0.02 | -39.87% |
| 2020 | $-0.03 | 69.06% |
| 2019 | $-0.02 | -69.73% |
| 2018 | $-0.06 | -63.09% |
| 2017 | $-0.16 | 1,308.70% |
| 2015 | $-0.01 | -48.20% |
| 2014 | $-0.02 | 167.47% |
| 2013 | $-0.01 | -72.52% |
| 2012 | $-0.03 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $18.99 | -118,787.50% |
US
|
|
| $6.12 | -38,350.00% |
US
|
|
| $1.38 | -8,700.00% |
CN
|
|
| $14.83 | -92,787.50% |
US
|
|
| $5.09 | -31,912.50% |
US
|
Questions about Telo Genomics Corp.'s earnings per share (EPS)
What is Telo Genomics Corp.'s earnings per share (EPS)?
Telo Genomics Corp.'s earnings per share (EPS) over the last twelve months is $-0.02, as of Jun 2026.
What was Telo Genomics Corp.'s earnings per share (EPS) in 2025?
In 2025, Telo Genomics Corp.'s earnings per share (EPS) was $-0.02, compared with $-0.03 in 2024.
How has Telo Genomics Corp.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Telo Genomics Corp.'s earnings per share (EPS) was highest in 2025 ($-0.02) and lowest in 2023 ($-0.04).
How does Telo Genomics Corp.'s earnings per share (EPS) compare with similar companies?
Telo Genomics Corp.'s earnings per share (EPS) ($-0.02) is lower than that of all 5 similar companies listed above. The highest among them is Thermo Fisher Scientific Inc., with $18.99.